The prevalence of MetS and the individual components of dyslipidemia between the APOE2 and APOE4 groups
| APOE2 | APOE4 | OR (95% CI) | p Value | |
|---|---|---|---|---|
| n | 130 | 136 | – | – |
| MetS (no/yes) | 86/44 (33.8%) | 81/55 (40.4%) | 1.327 (0.806 to 2.186) | 0.266 |
| Abdominal obesity (no/yes)* | 46/84 (64.6%) | 32/104 (76.5%) | 1.78 (1.042 to 3.039) | 0.034 |
| Hypertension (no/yes)* | 67/63 (48.5%) | 49/87 (64.0%) | 1.888 (1.156 to 3.085) | 0.011 |
| Hypertriglyceridaemia (no/yes) | 61/69 (53.1%) | 52/84 (61.8%) | 1.428 (0.877 to 2.327) | 0.152 |
| Hypercholesterolaemia (no/yes)* | 120/10 (7.7%) | 112/24 (17.6%) | 2.571 (1.177 to 5.617) | 0.015 |
| Hyperglycaemia (no/yes) | 114/16 (12.3%) | 125/11 (8.1%) | 0.627 (0.299 to 1.407) | 0.255 |
| Low HDL-C (no/yes) | 103/27 (13.6%) | 115/21 (10.6%) | 0.697 (0.371 to 1.307) | 0.259 |
Pearson’s χ2 test was used to analyse the differences.
Power by YOZOSOFT.
*The mean difference was significant at the 0.05 level.
HDL-C, high-density lipoprotein cholesterol; MetS, metabolic syndrome.